Meta-analysis of therapeutic efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension

Abstract

Abstract: AIM: To evaluate the clinical efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension by Meta-analysis. METHODS: Pubmed, Web of Science, CNKI and Wanfang Database were searched for combination of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan on hypertension treatment using the key words “amlodipine”, “amiloride/hydrochlorothiazide”, “telmisartan” and “hypertension”, supplemented literature recourse method to retrieve. The effectiveness and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan agents and overall effect tests based on strict quality evaluation of clinical trials. RESULTS: 13 literatures and 16 192 patients were included in this study, which consisted of 8 098 cases in amiloride/hydrochlorothiazide group and 8 094 cases in telmisartan group. The result of homogeneity test of efficacy was:χ²=14.50, df=12,P=0.27;while that of safety was χ²=5.86,df=7,P=0.56. The combined ORs and 95％CIs were 0.93,0.81-1.06 for efficacy and 1.23,1.04-1.45 for safety,respectively. CONCLUSION: There is no significant difference in therapeutic efficacy between amlodipine plus amiloride /hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension, but amlodipine plus telmisartan is safer and has less adverse reaction.

Key words: amiloride/hydrochlorothiazide, amlodipine, telmisartan, mild-to-moderate hypertension, Meta-analysis

CLC Number:

R969.1

ZUO Shan-ru, LIU Shi-kun, ZUO Xiao-cong, LI Bing, WU Cui-fang, LI Zuo-jun, WANG Chun-jiang, DENG Zhen-zhen, MA Yu-tao. Meta-analysis of therapeutic efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 70-74.

References

[1] 刘红艳,彭辉,刘奥博,等.中国人原发性高血压危险因素Meta分析[J].中国心血管杂志,2009,14(3):205-209.
[2] 李颖,崔嵘,袁洪,等.小剂量氨氯地平联合用药治疗老年高血压的疗效和安全性评价[J].中国老年学杂志,2010,30(8):1021-1024.
[3] 董凯霞. 小剂量氨氯地平联合复方阿米洛利治疗老年高血压的疗效及安全性[J].中国老年学杂志,2012,32(17):3671-3672.
[4] 桑海强,宁建平,孙明,等.初始联治疗策略对高血压患者的疗效及肾功能的影响[J].医学临床研究,2010,27(4):610-613.
[5] 周展.参加国家十一五课题《中国高血压综合防治研究》的体会[D].福建:福建医科大学,2009.
[6] 贾颖,袁洪,黄志军,等. 氨氯地平为基础的不同用药方案治疗原发性高血压的疗效观察[J].现代医药卫生,2010,26(19):2883-2885.
[7] 何小娟,何晓骥. 氨氯地平联合替米沙坦与氨氯地平联合阿米洛利治疗原发性高血压对比分析[J].中国医药指南,2011,9(22):78-79.
[8] 舒瑛,张艳梅,陈复琼,等. 氨氯地平联合替米沙坦或复方阿米洛利的疗效及安全性比较[J].药物流行病学杂志,2011,20(6):275-278.
[9] 牛惠英. 氨氯地平联合复方阿米洛利或替米沙坦治疗原发性高血压疗效比较[J].中西医结合心脑血管病杂,2011,9(6):672-674.
[10] 俞蔚, 唐新华, 王文,等.氨氯地平联合复方阿米洛利或替米沙坦对高血压患者降压疗效的相关临床因素分析[J].中国临床药理学与治疗,2010,15(11):1273-1278.
[11] 孙尚文,路方红,孙颖,等. 氨氯地平联合复方阿米洛利或联合替米沙坦对高血压患者颈动脉粥样硬化的对比研究[J].中华高血压杂志,2011,19(8):763-767.
[12] 沈江山.氨氯地平分别与替米沙坦及复方阿米洛利联合应用治疗轻中度高血压的临床研究[D].南昌:南昌大学,2010.
[13] Ma L, Wang W, Zhao Y, et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study [J]. Am J Cardiovasc Drugs, 2012,12 (2):137-142.
[14] Lu F, Zhao Y, Liu Z, et al. A 48-week study of amlodipine plus amiloride? hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension[J]. Int J Clin Pract, 2012, 66(8):792-799.
[15] 汪全海,贺连平,陈燕,等.氨氯地平联合替米沙坦改善高血压合并糖尿病患者微蛋白尿效果的Meta分析[J].中国临床药理学与治疗学,2013,18(7):774-777.